The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
7,300 jobs Number of planned job losses
Announcement Date
2 February 2012
Employment effect (start)
2 February 2012
Foreseen end date
1 January 2014
Description
Anglo-Swedish pharmaceuticals firm AstraZeneca plans to cut 7,300 jobs worldwide as part of a new restructuring plan.
The firm estimates that 3,750 of the job losses will occur in its sales, general and administrative division. The number of sales and marketing regions has been reduced from five to three, and smaller countries will be clustered together for the purposes of commercial organisation. Increased use of call centres and digital channels for customer communications will provide further savings in this area.
In research and development - a division currently employing around 15,700 people - roughly 2,200 jobs will be cut. This is in part the consequence of an approach under which smaller AstraZeneca teams will collaborate with external partners, to increase flexibility.
The remaining 1,350 job losses will come from the firm's operations function, with a focus on support functions.
The UK's GMB Union has reported that 250 to 300 research and development jobs will be lost at one site in Cheshire, while further back office cuts will affect other UK locations. In Sweden, the workforce in Södertälje will be reduced by between 1100 and 1200 workers due to the closure of research facilities.
Increased competition and the expiry of patents on key AstraZeneca products have contributed to the need for cuts, according to the company.
Sources
2 February 2012: AstraZeneca website
2 February 2012: The Local
2 February 2012: BBC News Website
Citation
Eurofound (2012), AstraZeneca, Internal restructuring in World, factsheet number 73042, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/73042.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
